Novo Nordisk is trading 10.5% down at $46.19 after signaling that its U.S. obesity-drug business is decelerating faster than investors expected ahead of its Q2 earnings release.
- The company flagged a worsening price squeeze in the U.S. obesity market, raising significant concerns regarding future growth and profit margins.
- The sharp downward move in pre-market trading has effectively erased all of the share price gains recorded during the prior week.
- Investors are reacting to the unexpected deceleration in a segment that has been the primary driver of the company's recent valuation.